XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements (Tables)
6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
Schedule of liabilities measured at fair value on the condensed consolidated balance sheet
The following are the liabilities measured at fair value on the condensed consolidated balance sheet at June 30, 2023 and December 31, 2022 using quoted price in active markets for identical assets (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3):
Level 1:
Quoted Prices
in Active
Markets for Identical
Assets
Level 2:
Significant
Other
Observable
Inputs
Level 3:
Significant
Unobservable
Inputs
Total at June 30,
2023
Total Gains (Losses) For The Three Months Ended June 30, 2023Total Gains (Losses) For The Six Months Ended June 30, 2023
Recurring fair value measurements
Private warrants $— $— $216 $216 $784 $1,784 
Stonepeak and Evolve unvested warrants$— $— $— $— $— $— 
Institutional/Accredited Investor warrants $— $— $290,632 $290,632 $143,010 $(71,748)
Derivative liability - non-controlling redeemable preferred shares$— $— $353,006 $353,006 $83,059 $6,219 
Total recurring fair value measurements$— $— $643,854 $643,854 $226,853 $(63,745)
Level 1:
Quoted Prices
in Active
Markets for Identical
Assets
Level 2:
Significant
Other
Observable
Inputs
Level 3:
Significant
Unobservable
Inputs
Total at December 31,
2022
Total Gains (Losses) For The Three Months Ended June 30, 2022Total Gains (Losses) For The Six Months Ended June 30, 2022
Recurring fair value measurements
Private warrants$— $— $2,000 $2,000 $251,000 $684,000 
Stonepeak and Evolve unvested warrants$— $— $— $— 4,334,000 8,677,000 
Institutional/Accredited Investor warrants$— $— $218,884 $218,884 $— $— 
Derivative liability - non-controlling redeemable preferred shares$— $— $359,225 $359,225 $(32,536)$20,936 
Total recurring fair value measurements$— $— $580,109 $580,109 $4,552,464 $9,381,936 
Schedule of fair value on a recurring basis
The following is a reconciliation of the opening and closing balances for the liabilities related to the warrants (Note 11) and derivative liability - non-controlling redeemable preferred shares measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the three and six months ended June 30, 2023:
Private warrants Stonepeak and Evolve unvested warrants Institutional/Accredited Investor warrants Non-controlling redeemable preferred shares - derivative liability
Balance at December 31, 2022$2,000 $— $218,884 $359,225 
Total (gains) losses for period included in earnings(1,000)— 214,758 76,840 
Balance at March 31, 2023$1,000 $— 433,642 $436,065 
Total (gains) losses for period included in earnings(784)— (143,010)(83,059)
Balance at June 30, 2023$216 $— $290,632 $353,006 
Schedule of fair value measurement inputs and valuation techniques
The following table presents the significant unobservable inputs and valuation methodologies used for the Company’s fair value measurements of non-recurring (level 3) Stonepeak and Evolve unvested warrants at June 30, 2023:
Series C Unvested WarrantsSeries D Unvested WarrantsSeries E Unvested WarrantsSeries F Unvested Warrants
Fair value (in millions)$—$—$—$—
Valuation methodologyMonte Carlo Simulation & Black Scholes Monte Carlo Simulation & Black ScholesMonte Carlo Simulation & Black ScholesMonte Carlo Simulation & Black Scholes
Capital expenditure forecast (in millions)$—$—$—$—
Probability of warrants vesting (a)—%—%—%—%
__________________
(a) During the second quarter ended June 30, 2022, the Company significantly lowered its forecast of Levo's capital deployments due to the passage by the United States Congress of the Infrastructure Investment and Jobs Act bill, and the related unveiling of the Environmental Protection Agency’s 2022 Clean School Bus rebates. The resulting lower forecast of capital deployments reduced the probabilities of the future vesting of the unvested warrants. Therefore, at June 30, 2023, the Company has determined that it is unlikely that the unvested warrants will vest.

The following table presents the significant unobservable inputs and valuation methodologies used for the Company’s fair value measurements of non-recurring (level 3) Stonepeak and Evolve unvested warrants at June 30, 2022:

Series C Unvested WarrantsSeries D Unvested WarrantsSeries E Unvested WarrantsSeries F Unvested Warrants
Fair value (in millions)$—$—$—$—
Valuation methodologyMonte Carlo Simulation & Black ScholesMonte Carlo Simulation & Black ScholesMonte Carlo Simulation & Black ScholesMonte Carlo Simulation & Black Scholes
Term (years)8.908.908.908.90
Risk free rate3.0%3.0%3.0%3.0%
Exercise price$15.0$20.0$30.0$40.0
Volatility56.0%56.0%56.0%56.0%
Capital expenditure forecast (in millions)$125.0$250.0$375.0$500.0
Probability of warrants vesting (a)—%—%—%—%
__________________
(a) During the second quarter ended June 30, 2022, the Company significantly lowered its forecast of Levo's capital deployments due to the passage by the United States Congress of the Infrastructure Investment and Jobs Act bill, and the related unveiling of the Environmental Protection Agency’s 2022 Clean School Bus rebates. The resulting lower forecast of capital deployments reduced the probabilities of the future vesting of the unvested warrants. Therefore, at June 30, 2022, the Company has determined that it is unlikely that the unvested warrants will vest.